News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Trius Therapeutics Files for IPO
November 9, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pehub.com -- Trius Therapeutics Inc., a San Diego-based developer of antibacterial drugs, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol TSRX, with Credit Suisse serving as lead underwriter.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Immunology and inflammation
Sanofi Keeps Immuno Deals Coming With Kali Bet Worth Potential $1B+
March 23, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
March 20, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
In Tight Deal Environment, Pharma May Need To Think Big
March 18, 2026
·
5 min read
·
Annalee Armstrong
Mergers & acquisitions
Pharma Is Ravenous for M&A Action but Late-Stage Supply Dwindles
March 11, 2026
·
5 min read
·
Annalee Armstrong